OM DETTA AVSNITT
The aesthetics industry is having two arguments about skincare retail. Both are a waste of breath.
In this episode of The Contraindication, I take on the two most circular debates in aesthetics right now: whether "medical-grade" is a real thing, and whether clinics are right to be furious that the brands they retail have gone direct-to-consumer.
My argument is that neither conversation touches the actual problem. Clinic retail was built on a moat: access to actives you couldn't get anywhere else. That moat has gone. Until clinics admit it, they'll keep debating labels and blaming brands instead of fixing a retail model that no longer works.
What You'll Hear:
- Why the medical-grade debate never ends: it rewards both sides. Defending the phrase makes you sound authoritative, and attacking it makes you sound clinically rigorous. Neither answers the commercial question.
- Why the D2C anger is aimed at the wrong target: brands going direct are reacting to the same market shift clinics are living through, and staying furious is a distraction from building something defensible.
- What clinics were really selling: not the product, and not even the ingredients, but access. Consumers now buy the same actives from Boots and overseas sites.
- What to build instead: sell the pathway, not the product. That means bundling skincare into treatment, charging for your diagnostic expertise, building continuity instead of transactions, and deciding which products are actually worth defending. It includes a real-world example from Wish Skin Health's system and Nuwave Clinic.
If you're ready to stop defending a retail model built on a moat that no longer exists, and start building one around your clinical expertise, this one's for you.
If you want support with your clinic's specific needs, you can book a Power Hour with Elly at theaestheticsmarketer.co.uk.
The Contraindication is produced by Urban Podcasts.
